Abstract:Pancreatic ductal adenocarcinoma (PDAC) is refractory to cytostatic and immuno-oncology therapeutic strategies, leaving surgical resection of the tumor as the only treatment that can significantly prolong survival. We are therefore exploring optimized treatment strategies targeting cancer cells as well as infiltrating immune cells and the tumor microenvironment (TME) in an autochthonous mouse model for PDAC. Single focal tumors are induced through in vivo electroporation of gene constructs into the pancreas which encode mutated Kras and facilitate knock out the tumor suppressor genes P53, Cdkn2a and/or Smad4 via CRISPR/Cas9. The resulting tumors recapitulate the human disease with respect to genetics, histology and TME composition. Furthermore, this model allows the generation of tumors reflecting different PDAC subtypes, as well as the resection of primary tumors in combination with the (neo-)adjuvant regimens. Like the human disease, these tumors are refractory to chemotherapy and immune checkpoint blockade, whereas targeted therapy by means of MEK inhibitors merely leads to temporary delay of tumor outgrowth. We therefore tested the combination of MEK inhibitor treatment with different, potentially complementary modalities. We found the combination with agonist anti-CD40 antibodies to be highly effective. Prominent regressions are observed, and in combination with primary tumor resection long-term complete responses can be achieved even in a metastatic variant of the model. Apart from the direct cytostatic impact of MEKi on the Kras-transformed tumor cells, the mechanism of action of this synergistic drug combination involves enhancement of the anti-tumor T-cell response, suppression of CD4+ Tregs, and reduction of MDSCs and M2-type macrophages in favor of M1-type pro-inflammatory macrophages. A second highly effective regimen as identified in our experiments involves the combination of MEK inhibitors with the multi-kinase inhibitor regorafenib. In contrast to the aforementioned regimen, the complementary action of these drugs involves modulation of the TME by regorafenib. While the clinical translation of the MEKi/CD40 Ab regimen is hampered by toxicity issues encountered with agonist anti-CD40 Ab, the synergy as observed in the MEKi/regorafenib regiment provides a tangible path towards clinical testing. Citation Format: Aline S. Konrad, Tanja Hägele, Stefan Zens, Caroline Vent, Moritz Hamberger, Sarah Baiker, Aron Maes, Carl-Stephan Leonhardt, Oliver Strobel, Oliver Politz, Dieter Zopf, Daniel Baumann, Julian Mochayedi, Rienk Offringa. Identification of synergistic drug combinations including MEK inhibitor and agents modulating the tumor microenvironment in an electroporation-induced pancreatic cancer model [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Pancreatic Cancer; 2023 Sep 27-30; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(2 Suppl) nr B079.

Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy

Mtorc1/autophagy-Regulated MerTK in Mutant BRAFV600 Melanoma with Acquired Resistance to BRAF Inhibition

Phase II Clinical Trial of Trametinib and Low-Dose Dabrafenib in Advanced, Previously Treated BRAFV600/NRASQ61 Wild-Type Melanoma (TraMel-WT)

Phase II Clinical Trial of Trametinib and Low-Dose Dabrafenib in Advanced, Previously Treated BRAF V600 /NRAS Q61 Wild-Type Melanoma (TraMel-WT)

BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS-mutant melanoma cells: Insights into mode of action and resistance mechanisms

Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers

Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity

Enhancing efficacy of the MEK inhibitor trametinib with paclitaxel in KRAS -mutated colorectal cancer

Cnsc-25. Concurrent Immune Checkpoint Blockade Enhances The Survival Benefit Of Clinically Relevant Mapk Pathway Inhibitors In A T Cell-Dependent Manner

Targeting EphA2 and DDR signaling can overcome the BRAF and MEK inhibitors acquired resistance in melanoma cell lines

BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma

BRAF and EGFR Inhibitors Synergize to Increase Cytotoxic Effects and Decrease Stem Cell Capacities in BRAF(V600E)-mutant Colorectal Cancer Cells.

Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma

Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6

Combined therapy of dabrafenib and an anti-HER2 antibody–drug conjugate for advanced BRAF-mutant melanoma

Combination Atezolizumab, Cobimetinib, and Vemurafenib as a Treatment Option in BRAF V600 Mutation-Positive Melanoma: Patient Selection and Perspectives

COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant Melanoma

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma

Combined BRAF, MEK, and heat-shock protein 90 inhibition in advanced BRAF V600-mutant melanoma

Abstract B079: Identification of synergistic drug combinations including MEK inhibitor and agents modulating the tumor microenvironment in an electroporation-induced pancreatic cancer model

Phase Ib study of dabrafenib, trametinib, irinotecan and cetuximab in BRAF V600E-mutated metastatic colorectal cancer.